Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses PD-1 and PD-L1 in various cancers.
Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses PD-1 and PD-L1 in various cancers.
PD-1 is a negative regulator of the immune system, preventing it from overactivating. The cancer takes advantage of this, Ribas says, by expressing PD-L1 and preventing an attack from the immune system. New anti-PD-1 and anti-PD-L1 agents re-expose the cancer to the immune system.
Not all cancers and all histologies express PD-L1, Ribas says. PD-L1 has been analyzed in many cancers, including melanoma, kidney cancer, lung cancer, head and neck cancer, and ovarian cancer, allowing for the possibility of broad activity. Agents in this space release a brake of the immune system, meaning that the immune system must be activated against the cancer for these agents to be effective. This remains an evolving paradigm, Ribas notes.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
April 24th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
Read More